LSTA

#4421
Lisata Therapeutics, Inc. Common Stock
4.53 USD
-9.22%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
4.53
4.53
年范围
1.81
5.06
日变化
-9.22%
每月变动
-10.12%
6个月变化
+92.77%
年变化
+126.50%
前一天收盘价
4.99
开盘价
4.53
买价
卖价
最低价
4.53
High
4.53
交易量
2
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 40.92 M
  • Employee 21
  • Founded 1980
  • CEO N/A
  • Website www.lisata.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNVDR4
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-0.97
市销率
95.05

Lisata Therapeutics Inc

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

新闻